Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Novadip's $22 Million B Round for Skeletal Tissue Therapies Includes HK Investor

publication date: Oct 28, 2021

Novadip Biosciences of Belgium raised $22 million in a Series B round from global investors including CR-CP Life Science Fund of Hong Kong. Novadip is a clinical stage company developing products to regenerate impaired skeletal tissue. Its proprietary 3M3 platform is a 3-dimensional, extracellular matrix that uses adipose-derived stem cells to deliver growth factors and miRNAs that mimic natural healing. The company's lead candidate is an autologous bone product aimed at diseases that include congenital pseudarthrosis of the tibia (CPT), a rare pediatric disease. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital